-
EP1326604
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1326604
| EP1326604 - COMBINATION OF AT LEAST TWO COMPOUNDS SELECTED FROM AN AT1-RECEPTORANTAGONIST OR AN ACE INHIBITOR OR A HMG-CO-A REDUCTASE INHIBITOR GROUPS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 27.03.2009 Database last updated on 26.07.2024 | Most recent event Tooltip | 27.03.2009 | Application deemed to be withdrawn | published on 29.04.2009 [2009/18] | Applicant(s) | For:BE
CH
CY
DE
DK
ES
FI
FR
GB
GR
IE
IT
LI
LU
MC
NL
PT
SE
TR
Novartis AG Lichtstrasse 35 4056 Basel / CH | For:AT
Novartis Pharma GmbH Brunner Strasse 59 1230 Wien / AT | [N/P] |
| Former [2006/29] | For:BE
CH
CY
DE
DK
ES
FI
FR
GB
GR
IE
IT
LI
LU
MC
NL
PT
SE
TR
Novartis AG Lichtstrasse 35 4056 Basel / CH | ||
| For:AT
Novartis Pharma GmbH Brunner Strasse 59 1230 Wien / AT | |||
| Former [2003/29] | For:BE
CH
CY
DE
DK
ES
FI
FR
GB
GR
IE
IT
LU
MC
NL
PT
SE
TR
Novartis AG Lichtstrasse 35 4056 Basel / CH | ||
| For:AT
Novartis Pharma GmbH Brunner Strasse 59 1230 Wien / AT | Inventor(s) | 01 /
DE GASPARO, Marc Es Planches 123a CH-2842 Rossemaison / CH | 02 /
GRAVES, Kurt, C. 4 Woodhull Drive Chester, NJ 07930 / US | [2003/29] | Representative(s) | Gros, Florent, et al Novartis AG Corporate Intellectual Property Patent & Trademark Department CH 4002 Basel / CH | [N/P] |
| Former [2003/29] | Gros, Florent, et al Novartis AG Corporate Intellectual Property, Patent & Trademark Department CH 4002 Basel / CH | Application number, filing date | 01931583.7 | 10.04.2001 | [2003/29] | WO2001EP04115 | Priority number, date | US20000196743P | 12.04.2000 Original published format: US 196743 P | [2003/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO0176573 | Date: | 18.10.2001 | Language: | EN | [2001/42] | Type: | A2 Application without search report | No.: | EP1326604 | Date: | 16.07.2003 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.10.2001 takes the place of the publication of the European patent application. | [2003/29] | Search report(s) | International search report - published on: | EP | 17.04.2003 | Classification | IPC: | A61K31/41, A61K31/40, A61K31/55, A61P9/08, A61P9/10 | [2003/29] | CPC: |
A61K31/401 (EP,US);
A61K31/435 (KR);
A61K31/41 (EP,US);
A61K31/55 (EP,US);
A61P13/12 (EP);
A61P15/10 (EP);
A61P3/00 (EP);
A61P3/04 (EP);
A61P3/06 (EP);
A61P3/10 (EP);
A61P43/00 (EP);
A61P5/14 (EP);
A61P7/10 (EP);
A61P9/00 (EP);
A61P9/08 (EP);
| C-Set: |
A61K31/401, A61K2300/00 (EP,US);
A61K31/41, A61K2300/00 (US,EP);
A61K31/55, A61K2300/00 (US,EP)
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2003/29] | Extension states | AL | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | RO | Not yet paid | SI | Not yet paid | Title | German: | KOMBINATION VON MINDESTENS 2 AUS EINER AT1-REZEPTOREN-ANTAGONIST- ODER EINER ACE-INHIBITOR- ODER EINER HMG-CO-A REDUKTASE INHIBITORGRUPPE SELEKTIERTE WIRKSTOFFE | [2003/29] | English: | COMBINATION OF AT LEAST TWO COMPOUNDS SELECTED FROM AN AT1-RECEPTORANTAGONIST OR AN ACE INHIBITOR OR A HMG-CO-A REDUCTASE INHIBITOR GROUPS | [2003/29] | French: | COMBINAISON D'AU MOINS 2 COMPOSES SELECTIONNES D'UN ANTAGONISTE DE RECEPTEURS AT1 OU D'UN INHIBITEUR DE ACE OU D'UN HMG-CO REDUCTASE | [2003/29] | Entry into regional phase | 12.11.2002 | National basic fee paid | 17.10.2003 | Designation fee(s) paid | 17.10.2003 | Examination fee paid | Examination procedure | 18.10.2001 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 17.10.2003 | Examination requested [2003/51] | 01.11.2008 | Application deemed to be withdrawn, date of legal effect [2009/18] | 08.12.2008 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2009/18] | Fees paid | Renewal fee | 02.05.2003 | Renewal fee patent year 03 | 03.05.2004 | Renewal fee patent year 04 | 02.05.2005 | Renewal fee patent year 05 | 02.05.2006 | Renewal fee patent year 06 | 02.05.2007 | Renewal fee patent year 07 | Penalty fee | Additional fee for renewal fee | 30.04.2008 | 08 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO9631234 (CIBA GEIGY AG [CH], et al) [X] 1-3,6,7,9 * page 1, paragraph 2; claims 1,2 *; | [X]WO9702032 (MERCK & CO INC [US], et al) [X] 1-3,6,7,9 * page 2, lines 7-24; claims 1,2,4,7-12 * * page 3, lines 19-25 *; | [X]WO9736874 (SMITHKLINE BEECHAM CORP [US], et al) [X] 1-3,6,7,9 * page 1, line 12; claims 11-13,20,21,42-47 * * page 8, lines 20-32 *; | [X]EP0930076 (SANKYO CO [JP]) [X] 1-3,6,7,9 * claims 1-6,24-26 *; | [X]US5981470 (AHMED ASIF SYED [GB]) [X] 1-3,6,7,9 * column 8, lines 33-39; claims 1-3 *; | [X] - RUILOPE L M ET AL, "SAFETY OF THE COMBINATION OF VALSARTAN AND BENAZEPRIL IN PATIENTS WITH CHRONIC RENAL DISEASE", JOURNAL OF HYPERTENSION, CURRENT SCIENCE, PHILADELPHIA, PA, US, (200001), vol. 18, no. 1, ISSN 0263-6352, pages 89 - 95, XP001056854 [X] 1-3,6,7,9 * abstract * DOI: http://dx.doi.org/10.1097/00004872-200018110-00003 | [X] - MERVAALA, EERO ET AL, "Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (AUG., 1999) VOL. 10, NO. 8, PP. 1669-1680., XP001071075 [X] 1-3,6,7,9 * abstract * | [X] - DE GASPARO, MARC (1) ET AL, "Protective effects of the combination of non hypotensive doses of valsartan and enalapril in spontaneously hypertensive rats with endothelial dysfunction.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY., (FEB., 2000) VOL. 35, NO. 2 SUPPL. A, PP. 248A. MEETING INFO.: 29TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN COLLEGE OF CARDIOLOGY. ANAHEIM, CALIFORNIA, USA MARCH 12-15, 2000, XP001061413 [X] 1-3,6,7,9 * the whole document * |